High dose-rate afterloading 192iridium prostate brachytherapy: feasibility report

Mate, Timothy P.; Gottesman, James E.; Hatton, John F.; Gribble, Michael; Hollebeke, Lynn Van

doi:10.1016/s0360-3016(98)00097-2

Cited by 200 publications

(42 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Urinary and Gastrointestinal complications rates were in concordance with the experience of other institutions using conformal high doses rate brachytherapy [19-22] and favourably with other 3-D conformal radiotherapy escalating series [14,15]. …”

Section: Discussionsupporting

confidence: 83%

“…Galalae et al reported 8-year bNED survival rate (free of clinical or biochemical evidence of disease) in the high-risk prognostic group of 64% [20]. Dattoli et al [21] and Mate et al [22] reported similar results. A recent report Stock et al reported 8-year actuarial biochemical control rate of 73% for patients with Gleason score 8-10 prostate cancer [23].…”

Section: Discussionmentioning

confidence: 86%

See 1 more Smart Citation

Long-term biochemical results after high-dose-rate intensity modulated brachytherapy with external beam radiotherapy for high risk prostate cancer

et al. 2012

View full text Add to dashboard Cite

BackgroundBiochemical control from series in which radical prostatectomy is performed for patients with unfavorable prostate cancer and/or low dose external beam radiation therapy are given remains suboptimal.The treatment regimen of HDR brachytherapy and external beam radiotherapy is a safe and very effective treatment for patients with high risk localized prostate cancer with excellent biochemical control and low toxicity.

show abstract

Section: Discussionsupporting

confidence: 83%

Section: Discussionmentioning

confidence: 86%

Long-term biochemical results after high-dose-rate intensity modulated brachytherapy with external beam radiotherapy for high risk prostate cancer

et al. 2012

View full text Add to dashboard Cite

show abstract

“…Meanwhile, the incidence of Grade 3 toxicity after EBRT was very rare [28]. HDR brachytherapy is associated with relatively severe GU toxicities, such as urethral stricture [11, 23, 24, 32]. Although the severity of GU toxicities in our study population was relatively high, all cases were manageable by medical or surgical intervention.…”

Section: Discussionmentioning

confidence: 86%

High-dose-rate brachytherapy and hypofractionated external beam radiotherapy combined with long-term hormonal therapy for high-risk and very high-risk prostate cancer: outcomes after 5-year follow-up

Ishiyama

Satoh

Kitano

et al. 2013

Journal of Radiation Research

View full text Add to dashboard Cite

The purpose of this study was to report the outcomes of high-dose-rate (HDR) brachytherapy and hypofractionated external beam radiotherapy (EBRT) combined with long-term androgen deprivation therapy (ADT) for National Comprehensive Cancer Network (NCCN) criteria-defined high-risk (HR) and very high-risk (VHR) prostate cancer. Data from 178 HR (n = 96, 54%) and VHR (n = 82, 46%) prostate cancer patients who underwent 192Ir-HDR brachytherapy and hypofractionated EBRT with long-term ADT between 2003 and 2008 were retrospectively analyzed. The mean dose to 90% of the planning target volume was 6.3 Gy/fraction of HDR brachytherapy. After five fractions of HDR treatment, EBRT with 10 fractions of 3 Gy was administered. All patients initially underwent ≥6 months of neoadjuvant ADT, and adjuvant ADT was continued for 36 months after EBRT. The median follow-up was 61 months (range, 25–94 months) from the start of radiotherapy. The 5-year biochemical non-evidence of disease, freedom from clinical failure and overall survival rates were 90.6% (HR, 97.8%; VHR, 81.9%), 95.2% (HR, 97.7%; VHR, 92.1%), and 96.9% (HR, 100%; VHR, 93.3%), respectively. The highest Radiation Therapy Oncology Group-defined late genitourinary toxicities were Grade 2 in 7.3% of patients and Grade 3 in 9.6%. The highest late gastrointestinal toxicities were Grade 2 in 2.8% of patients and Grade 3 in 0%. Although the 5-year outcome of this tri-modality approach seems favorable, further follow-up is necessary to validate clinical and survival advantages of this intensive approach compared with the standard EBRT approach.

show abstract

“…Stromberg et al initiated the use of three implants with a single fraction of 5.5 Gy each [5], while Mate et al used a single implant with four HDR fractions of 3–4 Gy each [6], and Martinez et al reported promising results using two or three implants with a single fraction of 5.5–11.5 Gy each [7]. Yoshioka et al reported a single implant with eight fractions of 5.5 Gy each for 5 days as monotherapy [8].…”

Section: High Dose Rate (Hdr) Brachytherapymentioning

confidence: 99%

Efficacy and Safety of High-Dose-Rate Brachytherapy of Single Implant with Two Fractions Combined with External Beam Radiotherapy for Hormone-Naïve Localized Prostate Cancer

Noda

Sato

Shirai

et al. 2011

Cancers

View full text Add to dashboard Cite

The purpose of this study was to evaluate the efficacy and safety of high-dose-rate (HDR) brachytherapy of a single implant with two fractions plus external beam radiotherapy (EBRT) for hormone-naïve prostate cancer in comparison with radical prostatectomy. Of 150 patients with localized prostate cancer (T1c–T2c), 59 underwent HDR brachytherapy plus EBRT, and 91 received radical prostatectomy. The median follow-up of patients was 62 months for HDR brachytherapy plus EBRT, and 64 months for radical prostatectomy. In patient backgrounds between the two cohorts, the frequency of T2b plus T2c was greater in HDR brachytherapy cohort than in prostatectomy cohort (27% versus 12%, p = 0.029). Patients in HDR brachytherapy cohort first underwent 3D conformal RT with four beams to the prostate to an isocentric dose of 50 Gy in 25 fractions and then, a total of 15–18 Gy in two fractions at least 5 hours apart. We prescribed 9 Gy/fraction for target (prostate gland plus 3 mm lateral outside margin and seminal vesicle) using CT image method for radiation planning. The total biochemical failure-free control rates (BF-FCR) at 3 and 5 years for the HDR brachytherapy cohort, and for the prostatectomy cohort were 92% and 85%, and 72% and 72%, respectively (significant difference, p = 0.0012). The 3-and 5-year BF-FCR in the HDR brachytherapy cohort and in the prostatectomy cohort by risk group was 100 and 100%, and 80 and 80%, respectively, for the low-risk group (p = 0.1418); 92 and 92%, 73 and 73%, respectively, for the intermediate-risk group (p = 0.0492); and 94 and 72%, 45 and 45%, respectively, for the high-risk group (p = 0.0073). After HDR brachytherapy plus EBRT, no patient experienced Grade 2 or greater genitourinay toxicity. The rate of late Grade 1 and 2 GI toxicity was 6% (n = 4). No patient experienced Grade 3 GI toxicity. HDR brachytherapy plus EBRT is useful for treating patients with hormone-naïve localized prostate cancer, and has low GU and GI toxicities.

show abstract

High dose-rate afterloading 192iridium prostate brachytherapy: feasibility report

Cited by 200 publications

References 19 publications

Long-term biochemical results after high-dose-rate intensity modulated brachytherapy with external beam radiotherapy for high risk prostate cancer

Long-term biochemical results after high-dose-rate intensity modulated brachytherapy with external beam radiotherapy for high risk prostate cancer

High-dose-rate brachytherapy and hypofractionated external beam radiotherapy combined with long-term hormonal therapy for high-risk and very high-risk prostate cancer: outcomes after 5-year follow-up

Efficacy and Safety of High-Dose-Rate Brachytherapy of Single Implant with Two Fractions Combined with External Beam Radiotherapy for Hormone-Naïve Localized Prostate Cancer

Contact Info

Product

Resources

About